August 9, 2012
Mylan Specialty L.P., a subsidiary of Mylan Inc. of the US, and Pfizer Inc. of the US have announced that the two companies have entered into a license agreement for the adjunct therapy treatment EpiPen Injection 0.3 mg/0.15 mg (adrenaline)...read more